Vimarsana
Biggest News Aggregation in the World

Higher Doses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Higher Doses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Higher Doses Today - Breaking & Trending Today

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease -October 27, 2023 at 09:26 am EDT - Vimarsana News

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease -October 27, 2023 at 09:26 am EDT

Published: October 27, 2023

- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer -targeting antibody, to inform dose selection, plus further analyses of...

Source: marketscreener.com
Related Topics:
United StatesJessica LaubEric SiemersAlex BraunStephen SallowayDaniel OconnellAcumen Pharmaceuticals IncDevelopment Of Novel Bioanalytical AssaysExchange CommissionAlpert Medical School Of Brown UniversityDrug AdministrationAnnual Clinical TrialsDanielo ConnellChief Executive OfficerTarget EngagementVarious DosesAmyloid Plaque LoadHigher DosesDid Not DevelopAlpert Medical SchoolBrown UniversityChief Medical OfficerNovel Bioanalytical AssaysAdditional Analyses UsingSensitive Assay
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data - Vimarsana News

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

Published: December 6, 2021

Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be... | December 6, 2021

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesKaitlin GallagherFranke WeiseBryan StuartStephanie AscherNaomi AokiChristi WaarichGerd BlobelStern Investor Relations IncDrug AdministrationEmbryonic Ectoderm DevelopmentReplay International NumberExchange CommissionInternational NumberFulcrum Therapeutics IncCorporate CommunicationsBerry Company Public RelationsClinical DevelopmentGlobenewswire IncPediatric HematologyAchieved MaximalHigher DosesFold InductionHbf Master Regulators
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition - Vimarsana News

BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition

Published: November 4, 2021

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced an oral...

Source: prnewswire.com
Related Topics:
United StatesMoran MeirPhilip SerlinTim MccarthyAmerican Society Of HematologyLifesci AdvisorsExchange Commission OnGeorgia World Congress CenterBiolinerx LtdAmerican SocietyAnnual MeetingChief Executive OfficerMobilize Hematopoietic Stem CellsAutologous Stem Cell TransplantationMultiple MyelomaAutologous Hematopoietic Cell TransplantationHigher DosesSubsets MobilizedRapid EngraftmentPost Hoc AnalysisSingle Cell Transcriptional ProfilingHematopoietic StemProgenitor Cells MobilizedCorrelative StudyHigh Affinity
Evolus Reports Third Quarter 2021 Results and Provides Business Update - Vimarsana News

Evolus Reports Third Quarter 2021 Results and Provides Business Update

Published: November 2, 2021

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Related Topics:
United StatesDavidk EricksonDavid MoatazediExchange Commission OnDrug AdministrationEvolus IncStrength Phase Ii Clinical ProgramExchange CommissionDaewoong Pharmaceutical Co LtdRecord QuarterRevenue GrewCash PositionDemonstrate ExtendedChief ExecutiveRecent CorporateEvolus FoundersInvestor RelationsPrivate Securities Litigation Reform ActMedytox Settlement AgreementsQuarterly ReportGross Profit MarginAdjusted Gross ProfitEvolus RewardsBotulinum Toxin TypeGlabellar Frown Lines